Tempest Therapeutics

Contributing Author

Recent Articles by Tempest Therapeutics

Feb-04	Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets TPST -6.30% TPST GlobeNewswire
Jan-20	Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders TPST -5.15% GlobeNewswire
Nov-26	Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST GlobeNewswire
Nov-25	Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST -23.26% GlobeNewswire
Nov-19	Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 TPST -48.59% GlobeNewswire
Nov-05	Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update TPST +9.10% GlobeNewswire
Aug-11	Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update TPST +9.99% TPST +8.83% GlobeNewswire
Jun-30	Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China TPST GlobeNewswire
Jun-11	Tempest Announces $4.6 Million Registered Direct Offering of Common Stock TPST -15.88% GlobeNewswire
Jun-05	Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC TPST +15.16% GlobeNewswire
May-13	Tempest Reports First Quarter 2025 Financial Results and Provides Business Update TPST GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.